Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.

Tagrisso (osimertinib) - AstraZeneca

Lazcluze (lazertinib) - J&J

vabametkib (ABN401) - Abion

http://www.ncbi.nlm.nih.gov/pubmed/41927036

Byoung Chul Cho; Dong Kwon Kim; Hyeon Bin Cho; Jii Bum Lee; Jin Woo Park; Mi Ra Yu; Su Jin Choi; Sun Min Lim; Sung Sook Lee; YeongMun Kim

Apr 3, 2026